...
首页> 外文期刊>Infection and immunity >Isotypes and Opsonophagocytosis of Pneumococcus Type 6B Antibodies Elicited in Infants and Adults by an Experimental Pneumococcus Type 6B-Tetanus Toxoid Vaccine
【24h】

Isotypes and Opsonophagocytosis of Pneumococcus Type 6B Antibodies Elicited in Infants and Adults by an Experimental Pneumococcus Type 6B-Tetanus Toxoid Vaccine

机译:实验性肺炎球菌6B型破伤风类毒素疫苗诱发的婴幼儿肺炎球菌6B型抗体的同型和调理吞噬作用。

获取原文

摘要

Streptococcus pneumoniae is a major respiratory pathogen of infants, children, and the elderly. Polysaccharide vaccines have been useful in adult populations but do not elicit protective immunity in infants and young children. To enhance their immunogenicity, vaccines of pneumococcal polysaccharides conjugated to proteins are being developed. In this study antibody levels and opsonic activities were compared in sera of infants and adults injected with pneumococcal polysaccharide type 6B (Pn6B) conjugated to tetanus toxoid (TT) (Pn6B-TT). Healthy infants were injected with Pn6B-TT; group A was injected at 3, 4, and 6 months of age, and group B was injected at 7 and 9 months of age. A booster injection was given at 18 months. Adults were injected once. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and their functional activities were measured by opsonophagocytosis of radiolabelled pneumococci. In adults, increases in immunoglobulin M (IgM), IgG, IgA, IgG1, and IgG2 to Pn6B were observed. Infants reached adult levels of IgG1 anti-Pn6B after the primary injections. After the booster injection the infant groups had total IgG- and IgM-Pn6B antibody levels similar to those of adults. After the booster injection, IgG1 was the dominant infant anti-Pn6B isotype and at a level higher than in vaccinated adults, but IgA and IgG2 antibodies remained at very low levels. Opsonic activity increased significantly after Pn6B-TT injections; the highest infant sera showed opsonic activity comparable to that of vaccinated adults. Overall, opsonic activity correlated best with total and IgG anti-Pn6B antibodies (r = 0.741,r = 0.653, respectively; n = 35) and was highest in sera with high levels of all Pn6B antibody isotypes. The results indicate the protective potential of a pneumococcal 6B polysaccharide protein conjugate vaccine for young infants.
机译:肺炎链球菌是婴儿,儿童和老年人的主要呼吸道病原体。多糖疫苗已在成人人群中使用,但并未在婴幼儿中引起保护性免疫。为了增强其免疫原性,正在开发与蛋白质缀合的肺炎球菌多糖疫苗。在这项研究中,比较了注射破伤风类毒素(TT)(Pn6B-TT)的6B型肺炎球菌多糖(Pn6B)注射的婴儿和成人的血清抗体水平和调理活性。健康婴儿注射了Pn6B-TT。 A组分别在3、4和6个月大时注射,B组在7和9个月大时注射。在18个月时加强注射。成人注射一次。通过酶联免疫吸附测定和放射免疫测定来测定抗体,并通过放射性标记的肺炎球菌的调理吞噬作用来测定其功能活性。在成年人中,观察到免疫球蛋白M(IgM),IgG,IgA,IgG1和IgG2对Pn6B的增加。初次注射后,婴儿达到成人的IgG1抗Pn6B水平。加强注射后,婴儿组的总IgG-和IgM-Pn6B抗体水平与成年人相似。加强注射后,IgG1是主要的婴儿抗Pn6B亚型,其水平高于接种疫苗的成年人,但IgA和IgG2抗体仍处于非常低的水平。 Pn6B-TT注射后调理活性明显增加;婴儿的最高血清显示出与疫苗接种的成年人相当的调理活性。总体而言,调理活性与总抗和IgG抗Pn6B抗体相关性最佳( r = 0.741, r = 0.653; n = 35)并且在所有Pn6B抗体同种型水平较高的血清中最高。结果表明,肺炎球菌6B多糖蛋白结合疫苗对年幼婴儿具有保护作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号